相关实验视频

Updated: Jun 20, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

梅西尼布:首次获得批准

¹Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

|July 21, 2024

概括

作为MEK 1/2抑制剂的tunlametinib在中国获得了对NRAS突变晚期黑色素瘤的有条件批准. 这一里程碑标志着在治疗具有RAS和RAF突变的固体瘤方面迈出了重要的一步.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

图内美提尼布是一种口服的,选择性的线素激活蛋白激酶激酶1和2 (MEK 1/2) 抑制剂.
它是针对携带RAS和RAF突变的固体瘤开发的,例如黑色素瘤,NSCLC,CRC和NF1状神经纤维瘤.

研究的目的:

总结一下tunlametinib的发展里程碑.
为突出其在中国针对特定癌症类型的首次有条件批准.

主要方法:

开发数据和临床试验结果的审查.
对监管提交和批准过程的分析.

主要成果:

在2024年3月在中国授予条件批准.
根据代用终点,批准用于NRAS突变晚期黑色素瘤患者在抗PD-1/PD-L1治疗后,基于代用终点.

结论:

梅西尼布的批准代表了针对RAS/RAF突变固体瘤的向治疗的重大进展.
这一发展为未来可能在其他适应症中获得批准铺平了道路.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.